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Abstract
Background: Current models of the mechanism by which intravesical BCG induces an anti-tumor
effect in urothelial carcinoma propose a secondary cellular immune response as principally
responsible. Our group has demonstrated that BCG mediated cross-linking of α 5 1 integrin
receptors present on the tumor surface elicits a complex biologic response involving AP1 and NF-
κ B signaling as well as the transactivation of immediate early genes. This study evaluated the direct
biologic effect of cross-linking α 5β 1 integrin on cell cycle progression and apoptosis in two human
urothelial carcinoma cell lines.
Methods: Two independent assays (MTT and Colony forming ability) were employed to measure
the effect of α 5β 1 cross-linking (antibody mediated or BCG) on cellular proliferation. Flow
cytometry was employed to measure effect of BCG and α 5β 1 antibody mediated cross-linking on
cell cycle progression. Apoptosis was measured using assays for both DNA laddering and Caspase
3 activation.
Results:  Results demonstrate that integrin cross-linking by BCG, or antibody mediated
crosslinking of α 5β 1 resulted in a decrease in proliferating cell number. BCG treatment or α 5β 1
cross-linking increased the percentage of cells in G0/G1, in both 253J and T24 cell lines. Peptide
mediated blockade of integrin binding site using RGDS reversed the effect BCG on both
proliferation and cell cycle arrest. Apoptosis in response to BCG was not identified by either DNA
laddering or Caspase 3 activation.
Conclusion: These findings show that BCG exerts a direct cytostatic effect on human urothelial
carcinoma cell lines. Cell cycle arrest at the G1/S interface is a mechanism by which BCG inhibits
cellular proliferation. This effect is duplicated by antibody mediated cross-linking of α 5β 1 and likely
occurs as a consequence of crosslink-initiated signal transduction to cell cycle regulatory genes.
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Background
Bacille Calmette Guerin (BCG) remains the most effective
available treatment option for non-muscle invasive
urothelial carcinoma. Its superiority, both in terms of pre-
venting recurrence and progression, has been demon-
strated in multiple studies.[1-3] The mechanism
responsible for BCG's superior anti-tumor activity is felt to
be principally a consequence of an immune mediated
response.[4] Investigators have shown the importance of
a cellular immune response in orthotopic animal models
of urothelial malignancy. The "effector" cell population
responsible for the anti-tumor activity is currently felt to
be natural killer (NK) cells.[4]
While an extensive literature supports an immune mecha-
nism as being responsible for a portion of BCG's anti-
tumor activity, a direct effect of BCG has been demon-
strated by other authors. Multiple studies have demon-
strated an in vitro anti-proliferative effect of BCG against
human urothelial carcinoma cell lines.[5,6] Other authors
have demonstrated a direct effect of BCG on other impor-
tant biologic end points such as invasion.[7] The precise
mechanism responsible for this direct effect is ill defined.
Work by others together with recent studies by our group
has demonstrated that BCG has a direct gene regulatory
effect in urothelial carcinoma cell lines. We have shown
that this response is mediated via signal transduction ini-
tiated as a consequence of BCG induced cross-linking of
α 5β 1 integrins present on the surface membrane of
urothelial carcinoma cells.[8] Activation of signaling
through NF-κ B and AP1 initiate the transactivation of
immediate early genes including interleukin 6 (IL-6).[9]
Given the prevalence of NF-κ B and AP1 response ele-
ments in the promoters of genes, it is likely that multiple
genes are activated as a consequence of BCG/α 5β 1 cross-
linking.
Historically, studies assessing a direct effect of BCG on
tumor cells were hampered by the need to add a bacterial
preparation to the culture media. In this setting it is diffi-
cult to separate a true direct anti-tumor effect of BCG from
culture artifact.[6] Changes in pH, byproducts of the BCG
preparation, and/or bacterial toxins have the potential to
influence experimental outcome and yet fail to represent
a relevant in vivo mechanism. The current study
employed a non-biologic model that reproduces BCG
induced signaling to determine whether BCG exerts a
direct anti-tumor effect. Our results show that BCG
decreases cell proliferation as measured by two separate
assays of cell viability. Cell cycle arrest at the G1/S inter-
face, rather than apoptosis, appears to be the mechanism
by which this response occurs. These results are repro-
duced by the non-biologic signaling model in which α 5β 1
integrin receptors are cross-linked via antibodies and
blocked by peptide fragments that inhibit the ability of
fibronectin (FN) to function as a bridge for BCG mediated
cross linking of these receptors.
Methods
Cell lines
The human transitional carcinoma cell lines 253J and T24
were obtained from American Type Cell Culture (Rock-
ville, MD). Cells were maintained at 37°C, 5% CO2 in
RPMI 1640 (Gibco BRL, Grand Island, NY) supplemented
with 10% fetal bovine serum (FBS), penicillin, and strep-
tomycin (complete media).
Bacillus Calmette-Guerin (BCG)
TICE BCG, living organisms of an attenuated, Bacillus of
Calmette and Guerin strain of Mycobacterium bovis were
used in the experiments (Organon Inc, West Orange, NJ).
Freeze dried BCG was reconstituted in complete media at
an estimated concentration of 2.5 × 107 viable organisms/
ml. (dilution assumed average viability of 4 × 108 organ-
isms per vial based upon manufacturer's specified range of
1 to 8 × 108 per vial)
Antibody mediated cross-linking
Antibody mediated cross-linking of α 5β 1 integrin was car-
ried out as previously described.[8] Briefly, the following
mouse mAbs were used: anti-α 5 and anti-β 1 Abs were
purchased from Santa Cruz Biotechnology (Santa Cruz,
CA). Affinity-purified F(ab')2  goat anti-mouse (GAM)
antibody was purchased form BioSource International.
Cells were resuspended in 10% FBS RPMI-1640 and cul-
tured at 37°C for 45 min after trypsinization, then resus-
pended in RPMI-1640 serum-free medium (4 × 107 cells/
300  µl/tube) and incubated with anti- 5 or anti- 1
integrin mAb (5 µg/ml) for 30 min at 4°C and washed
with cold phosphate buffered saline (PBS). To initiate
receptor cross-linking, F(ab')2 goat anti-mouse F(ab')2 Ab
(100 µg/ml) was added after warming the cells to 37 C in
RPMI-1640 medium Cells were incubated at 37C. Cells
were harvested by pelleting the cells for 5 min at 500 × g.
Cell viability assay (MTT)
For the determination of the cell viability, we estimated
cellular bioreduction of 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyl tetrazolium bromide (MTT) subsequent to cell
exposure to either BCG or antibody mediated α 5β 1 cross-
linking.[10] A 200 µl volume of an exponentially growing
cell suspension (1 × 104 cells/ml) was seeded into a 96-
well microtiter plate. Twenty-four hours later 20 µl of
BCG at a ratio of 50:1 BCG to cells was added. After incu-
bation for 1, 2, 3, or 6 days at 37°C, 20 µl of MTT solution
(5 mg/ml in phosphate buffered saline, PBS) was added to
each well and the plates were incubated for a further 2 hr
at 37°C. 200 µl of lysis buffer (20% SDS in 50% DMF)
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was added to each well and cells were continuously incu-
bated for a further 2 hr at 37°C. Optical density was meas-
ured at 570 nm. Each experiment was performed in 3
replicate wells for each treatment and carried out inde-
pendently a minimum of 3 times.
Colony forming assay
Colony outgrowth of human urothelial carcinoma cells
following exposure to BCG or antibody mediated cross-
linking of α 5β 1 was measured using a colony forming
assay. 1 × 105 of 253J or T24 cells were seed in 48-well
plate with 1640 medium plus 10% FBS. After 24 hours
cells were treated with 1 × 107 BCG. After 1, 2, 3, or 6 days
incubation, the cells were trypsinized with 0.1 ml of
Trypsin-EDTA per well. Trypsinized cells were resus-
pended in a 10 ml total volume of minimal essential
medium (MEM) plus 20%FBS. 0.2 ml of this cell suspen-
sion was transferred into MEM plus 5%FBS at total vol-
ume of 25 ml. Five ml of this final cell suspension was
seeded onto grid marked 60 mm culture plate with grid.
Three plates were included for each group. The cells were
incubated at 37°C. After 7 days of incubation, 0.5 ml of
2.5% glutaraldehyde (Sigma, St. Louis, MO) was directly
added to each plate. The plates were incubated at room
temperature for 45 min. The media and glutaraldehyde
was aspirated and 1 ml of Wright-Giesma solution (EM
Science, Gibbstown, NJ) added for 30 minutes to stain the
colonies. One ml of Buffer Solution (LabChem Inc, Pitts-
burgh, PA) was added and the plates incubated at room
temperature for an additional 30 min. The plates were
gently rinsed under flowing tap water. After drying, the
colonies were manually counted under magnification. For
assay purposes, colonies were defined as consisting of 20
or more cells. For experiments employing antibody medi-
ated cross-linking of α 5 integrin, 1 × 105 of 253J or T24
cells were cultured in 48-well plate with 1640 plus 10%
FBS at 37°C. After 24 hours, the media was changed to
medium containing 5 µg/ml mouse monoclonal α 5 anti-
body. The cells were incubated at 4°C for 45 min and then
washed twice with serum free 1640 medium. Cross link-
ing was achieved by incubating the cells with media con-
taining GAM (10 µg/ml) at 37°C for 48 hrs. The CFA was
performed as described as the above. Untreated cells, cells
exposed to only primary antibody, and cells exposed to
secondary antibody served as controls.
Flow cytometry
Flow cytometry was employed to quantify the cell cycle
compartmentalization of TCC lines following exposure to
BCG or antibody mediated cross-linking of α 5β 1. 5 × 106
cells/per 6 cm dish were synchronized using serum starva-
tion for 60 hours prior to the start of the experiment. At
time zero, cells were exposed to BCG and 10% fetal
bovine serum (FBS) at a ratio of 50:1 BCG to cells or to
10% FBS alone. After 24 or 48 hours cells were
trypsinized, centrifuged at 1500 rpm for 5 min, washed
with PBS, and then treated with 50 µg/ml RNase A
(Sigma). DNA was stained with 50 µg/ml propidium
iodide for 10 min at room temperature and cell cycle anal-
ysis performed.
Apoptosis assay
Induction of apoptosis in response to BCG exposure or
antibody mediated cross-linking of α 5β 1 was determined
by measuring DNA fragmentation and activation of the
Caspase 3 pathway.[11] For DNA fragmentation, 1 × 106
253J cells in 1640 plus 10%FBS were seeded in 6 cm
plates. The following day cells were treated with 1 × 108of
BCG for 48 hrs. Non-adherent BCG was washed from the
plate and cells harvested in a digestion solution, consist-
ing of 100 mM NaCL, 10 mM Tris,10 mM EDTA, 0.5%
SDS, and 0.1 mg/ml Proteinase K, pH8.0. After overnight
digestion at 50°C, the cell lysates were extracted with phe-
nol/chloroform and the DNA in the aqueous phase pre-
cipitated with ethanol and resuspended in Tris-EDTA
buffer. After digestion with 5 µg/ml RNase A for 1 hr, DNA
was re-precipitated and DNA samples were electrophoret-
ically separated on 1.5% agarose gel containing ethidium
bromide (0.5 µg/ml). DNA was visualized by a UV transil-
luminator and the gels photographed.
In the caspase 3 assay, 253J cells were seeded at 1 × 106 in
6 cm plates. The next day cells were treated with BCG at a
ratio of 1 to 50 for 6 hours. At intervals following BCG
exposure, cells were harvested with trypsinization, washed
once in PBS, fixed and permeabilized using the Cytofix/
Cytoperm Kit (BD Biosciences) for 20 min at room tem-
perature (RT), pelleted and washed with Perm/Wash
buffer. Cells were then stained with anti-active caspase-3
mAb using 20 ug/1 × 106 cells for 60 min at room temper-
ature in the dark. Following incubation with the Ab, cells
were washed in Perm/Wash Buffer and analyzed by flow
cytometry.
All experiments were performed in triplicate. Results are
shown as the average value +/- one standard error.
Results
BCG inhibits urothelial carcinoma cell proliferation
Figures 1 and 2 demonstrate the effect of BCG exposure
on the viability of the human urothelial carcinoma cell
lines 253J and T24 as measured by the MTT and CF assays
respectively. Both cell lines, in both assays, demonstrated
a decrease in cell viability. Three days following BCG
exposure, the viability of 253J and T24 cells was 41% and
58% of control values in the MTT assay. In the CF assay,
colony counts were decreased in the 253J and T24 cells to
27% and 24 % respectively of control values after 3 days
of exposure.BMC Urology 2005, 5:8 http://www.biomedcentral.com/1471-2490/5/8
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Antibody mediated cross-linking of α 5β 1 integrin inhibits 
urothelial carcinoma cell proliferation
Figures 3 and 4 demonstrate the effect of antibody medi-
ated α 5β 1 cross-linking on the viability of the human
urothelial carcinoma cell lines 253J and T24 as measured
by the MTT and CF assays respectively. Cross-linking
decreased viability as measured by the MTT assay to 78%
and 77% of untreated controls in the 253J and T24 lines
at 3 days. Colony forming ability was similarly decreased
in both cell lines with the average colony count reduced to
23% and 42% of untreated controls in the respective cell
lines.
BCG induces cell cycle arrest at the G1/S interface
Figure 5 demonstrates the effect of BCG exposure on cell
cycle compartmentalization in 253J and T24 cells. Follow-
ing BCG exposure, the percentage of cells in G0/G1
increased 40% and 75% in the respective cell lines. The
increase in G phase population was mirrored by a
decrease in the percent of cells in S phase. The S phase cell
fraction in BCG treated cells represented 60% and 65% of
the control groups in 253J and T24 cells respectively.
Antibody mediated α 5β 1 integrin cross-linking induces cell 
cycle arrest at the G1/S interface
Figure 6 demonstrates the effect of antibody mediated
α 5β 1 cross-linking on cell cycle compartmentalization in
253J and T24 cells. Following cross-linking, the percent-
age of cells in G0/G1 increased 29% and 48% in the
respective cell lines. The increase in G phase population
was mirrored by a decrease in the percent of cells in S
phase. The S phase cell fraction in cross-linked cells repre-
sented 71% and 60% of the control groups in 253J and
T24 cells respectively.
BCG decreases the proliferation of human urothelial carci- noma cell lines as measured by the MTT assay Figure 1
BCG decreases the proliferation of human urothelial carci-
noma cell lines as measured by the MTT assay. Exposure of 
either 253J or T24 cells to BCG resulted in a decrease in via-
ble cell number as measured by the optical density of the 
metabolic product. The day represents the duration of expo-
sure to BCG
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
Day1 Day3 Day6
Days post-BCG
O
D
Untreated 253J
BCG 253J
Untreated T24
BCG T24
BCG decreases the proliferation of human urothelial carci- noma cell lines as measured by Colony Forming assay Figure 2
BCG decreases the proliferation of human urothelial carci-
noma cell lines as measured by Colony Forming assay. Expo-
sure of either 253J or T24 cells to BCG results in a time 
dependent decrease in viable cell number as measured by 
colony outgrowth. The day represents the duration of expo-
sure to BCG.
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Antibody mediated cross-linking of a5b1 integrin decreases the proliferation of human urothelial carcinoma cell lines as meas- ured by the MTT assay Figure 3
Antibody mediated cross-linking of a5b1 integrin decreases the proliferation of human urothelial carcinoma cell lines as meas-
ured by the MTT assay. Results are shown for a5 cross-linking in both 253J cells (figure 3a) and T24 cells (Figure 3b). Identical 
results were obtained when cross-linking was performed using antibodies to b1 (data not shown).
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Peptide blockade of integrin fibronectin binding sites using 
RGDS reverses the effect of BCG on proliferation and cell 
cycle arrest
BCG attaches to the cell surface via a fibronectin bridge
linking mycobacterial receptors to cell surface
integrins.[12-14] Mycobacterial binding of multiple
integrin bound fibronectin molecules can affect crosslink-
age of integrin receptors.[8] Blocking the ability of FN to
bind to either cellular or mycobacterial receptors pre-
cludes BCG attachment to the cell surface. [8,14] This
series of experiments employed a competitive inhibitor of
FN binding to integrins (RGDS) to assess the effect of
inhibiting BCG binding to integrin receptors on the bio-
logic response to BCG. While RGDS competitively inhib-
its the ability of FN to function as an opsonin for BCG
binding (effectively inhibiting BCG/integrin interaction),
prior studies have demonstrated that RGDS does not
effect integrin mediated signaling initiated in response to
antibody mediated cross linking of α 5β 1.[8] 253J cells
were pre-incubated with RGDS or the control (non-block-
ing) peptide RGES for 1 hour prior to BCG exposure. The
MTT and flow cytometric assays were then carried out as
described above. Controls included each peptide alone,
BCG alone, and untreated cells. In the MTT assay 2 con-
centrations of both the blocking and control peptides
were employed (100 or 250 ug/ml). The 250 ug/ml con-
centration was used in the flow cytometry assay.
Figure 7 demonstrates the effect of integrin blockade on
the anti-proliferative effect of BCG as measured by MTT
assay. RGDS reduced the BCG effect in a "dose-response"
manner with a maximal 4 fold inhibition at the 250 ug/
ml concentration. RGES had no effect. In the flow cyto-
metric assay, RGDS inhibited G1 arrest. The BCG induced
increase in the G1 fraction was reduced by 60% in RGDS
treated cells. RGES pretreatment had no effect on G1 or S
phase fraction compared to controls (Figure 8).
BCG does not induce an apoptotic response in urothelial 
carcinoma cell lines
A series of experiments were conducted to determine if
BCG exposure induced apoptosis in either the 253J or T24
cell lines. Gel electrophoresis of cellular DNA obtained at
intervals following BCG exposure failed to demonstrate
the laddering associated with apoptosis. Flow cytometry
for the apoptotic pathway enzyme caspase 3 failed to
Antibody mediated cross-linking of α 5β 1 integrin decreases  the proliferation of human urothelial carcinoma cell lines as  measured by Colony Forming assay Figure 4
Antibody mediated cross-linking of α 5β 1 integrin decreases 
the proliferation of human urothelial carcinoma cell lines as 
measured by Colony Forming assay.
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6a and 6b. Cell cycle compartmentalization in 253J (Figure 6a) and T24 (Figure 6b) cells following antibody mediated cross-link- ing of α 5β 1 integrin Figure 6
6a and 6b. Cell cycle compartmentalization in 253J (Figure 6a) and T24 (Figure 6b) cells following antibody mediated cross-link-
ing of α 5β 1 integrin. Similar to the effect observed in response to BCG, antibody mediated cross-linking resulted in an accumu-
lation of cells in G0-G1 with a concomitant decrease in the S-phase fraction.
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demonstrate activation of this enzyme in response to
BCG. (Data not shown)
Discussion
The anti-tumor effect of BCG is well established. Clinical
experience, the results of animal models, as well as in vitro
experiments provide data in clear support of this effect.
While an anti-tumor effect of BCG is certain, the mecha-
nism through which this occurs is less clear. In vivo ani-
mal models of BCG's anti-tumor effect suggest a critical
role for a cell mediated immune response. At the same
time, in vitro studies using human urothelial cell lines
identify a direct effect of BCG. The relative contribution of
these two possible mechanisms to BCG's clinical anti-
tumor activity is unknown.
A number of studies suggest that a direct anti-tumor effect
is at least in part responsible for BCG's activity. Work by
Pryor, Ciao, and Sasaki all have reported a direct anti-pro-
liferative effect of BCG.[5,6,15] Liu et al demonstrated
that BCG, as a consequence of its interaction with cell sur-
face bound fibronectin, abrogates invasion and motility
of urothelial carcinoma cell lines.[7] Cellular internaliza-
tion of BCG, with resultant alterations in reactive oxygen
species and nitric oxide, has been proposed as a mecha-
nism contributing to direct BCG mediated cytotoxicity.
[16,17]
Fibronectin functions as an opsonin, linking BCG to cell
surface fibronectin receptors of which α 5β 1 integrin is the
predominate FN receptor on urothelial cells. This linkage
is a requisite step for BCG's antitumor activity.[14] Rather
than constituting a passive interaction, our prior reports
have shown that FN mediated BCG adherence to the
urothelial carcinoma surface has a pharmacogenetic effect
as exemplified by transactivation of IL-6.[9] This effect is
mediated through signal transduction pathways involving
NF-κ B and AP-1. BCG induced signaling and gene trans-
activation pathways are identical to those observed in
response to antibody mediated cross linking of α 5β 1.[8]
Strategies that prevent the ability of FN to function as an
opsonin, including competitive inhibition of FN receptors
using RGDS and simultaneous saturation of mycobacte-
rial and cell surface FN receptors using excess exogenous
FN, inhibit the signaling and transactivation responses to
The effect of BCG on 253J Cellular Proliferation as measured  by MTT assay Figure 7
The effect of BCG on 253J Cellular Proliferation as measured 
by MTT assay. Peptide mediate integrin blockade (RGDS) 
reversed the anti-proliferative effect of BCG in a dose-
response manner. The control peptide RGES had no effect.
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BCG.[8,18] The current report moves beyond the details
of the signaling pathway to examine the biologic effect of
BCG induced signaling on a tumor biologic end point
with clear treatment relevance.
Consistent with what has been reported by others, our
results demonstrate that BCG exerts a direct anti-prolifer-
ative effect on human urothelial carcinoma cell lines. The
observed anti-proliferative effect does not appear to occur
as a consequence of apoptosis. To our knowledge this
report is the first to identify cell cycle arrest at the G1/S
interface as a mechanism by which BCG exerts an anti-
proliferative effect. As was the case for BCG induced sign-
aling and gene transactivation, this effect was reproduced
using antibody mediated cross-linking of α 5β 1 integrin.
Elimination of the opsonin function of fibronectin using
the peptide competitive inhibitor RGDS, effectively block-
ing the ability of BCG to bind integrin receptors, reversed
the biologic effects of BCG. These findings, together with
the results of prior studies, demonstrate that a portion of
the biologic response to BCG occurs as a consequence of
FN mediated binding of BCG to integrin receptors present
on the urothelial cell surface. The failure of simple
integrin ligation to simulate the BCG response, the ability
of antibody mediated crosslinking of α 5β 1 integrin to
duplicate the BCG response, the central role of FN in the
biologic response to BCG, together with the predomi-
nance of α 5β 1 as the principal FN binding integrin on
urothelial cells, strongly supports a model in which the
biologic response of the tumor cell to BCG occurs as a
consequence of BCG crosslinking of α 5β 1 integrin
receptors.
The results of this study have direct clinical relevance. The
demonstration that BCG has a direct anti-tumor effect
opens this pathway for potential manipulation to
improve treatment outcome. This is important given the
fact that 30% of patients are BCG refractory, and that the
long-term durability of response to BCG is limited.
Finally, and equally important, the dissection of the path-
way through which BCG exerts an anti-tumor effect will
allow us to move further towards our ultimate goal of
eliminating the need to expose patients to the risk of a via-
ble biologic organism and perhaps allow the develop-
ment of less toxic equally effective treatment approaches.
Conclusion
BCG, as a consequence of integrin cross-linking, exerts
direct anti-tumor effect against human urothelial carci-
noma cell lines. Cell cycle arrest at the G1/S interface,
rather than apoptosis, is a mechanism contributing to
BCG's anti-proliferative effect. Additional studies will be
required to define the molecular pathways that contribute
to this response.
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